Response by Kato et al to Letter Regarding Article, "Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus"

被引：1
|
作者：
Kato, Eri T. [1 ]
Sabatine, Marc S. [2 ]
Wiviott, Stephen D. [2 ]
机构：
[1] Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Kyoto, Japan
[2] Brigham & Womens Hosp, Cardiovasc Div, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA
来源：
CIRCULATION | 2019年 / 140卷 / 18期
关键词：
D O I：
10.1161/CIRCULATIONAHA.119.042848
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E740 / E741
页数：2
相关论文
共 50 条
  • [1] Letter by Elghazaly et al Regarding Article, "Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus"
    Elghazaly, Hussein
    Hajiev, Saur
    Singh, Parminder
    [J]. CIRCULATION, 2019, 140 (18) : E738 - E739
  • [2] Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
    Kato, Eri T.
    Silverman, Michael G.
    Mosenzon, Ofri
    Zelniker, Thomas A.
    Cahn, Avivit
    Furtado, Remo H. M.
    Kuder, Julia
    Murphy, Sabina A.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John P. H.
    Bonaca, Marc P.
    Ruff, Christian T.
    Desai, Akshay S.
    Goto, Shinya
    Johansson, Peter A.
    Gause-Nilsson, Ingrid
    Johanson, Per
    Langkilde, Anna Maria
    Raz, Itamar
    Sabatine, Marc S.
    Wiviott, Stephen D.
    [J]. CIRCULATION, 2019, 139 (22) : 2528 - 2536
  • [3] Letter by Wang et al Regarding Article, "Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks"
    Wang, Daxin
    Chen, Tian
    Yang, Xinquan
    [J]. CIRCULATION, 2019, 140 (16) : E720 - E721
  • [4] Response by Zelniker et al to Letter Regarding Article, "Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial"
    Zelniker, Thomas A.
    Raz, Itamar
    Sabatine, Marc S.
    Wiviott, Stephen D.
    [J]. CIRCULATION, 2020, 142 (10) : E129 - E130
  • [5] Response by Figtree et al to Letter Regarding Article, "Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)"
    Figtree, Gemma A.
    Radholm, Karin
    Neal, Bruce
    [J]. CIRCULATION, 2019, 139 (03) : 418 - 419
  • [6] Letter to the Editor regarding the article "The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions" Response
    Ofstad, Anne Pernille
    Atar, Dan
    Gullestad, Lars
    Langslet, Gisle
    Johansen, Odd Erik
    [J]. HEART FAILURE REVIEWS, 2018, 23 (05) : 819 - 819
  • [7] Letter by Chen et al Regarding Article, "Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial"
    Chen, Zhi-Qing
    Chen, Feng
    Li, Lang
    [J]. CIRCULATION, 2020, 142 (10) : E127 - E128
  • [8] Letter to the Editor regarding the article “The heart failure burden of type 2 diabetes mellitus—a review of pathophysiology and interventions”
    Michael Dandel
    Gerd Wallukat
    Roland Hetzer
    [J]. Heart Failure Reviews, 2018, 23 : 817 - 818
  • [9] Response by Sattar et al to Letters Regarding Article, "Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks"
    Sattar, Naveed
    Rawshani, Araz
    Franzen, Stefan
    [J]. CIRCULATION, 2019, 140 (16) : E724 - E725
  • [10] Response by Zinman et al to Letter Regarding Article, "Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk"
    Zinman, Bernard
    Inzucchi, Silvio E.
    Diener, Hans Christoph
    [J]. STROKE, 2017, 48 (09) : E256 - E257
12345